0001209191-18-052587.txt : 20180928
0001209191-18-052587.hdr.sgml : 20180928
20180928170135
ACCESSION NUMBER: 0001209191-18-052587
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20180919
FILED AS OF DATE: 20180928
DATE AS OF CHANGE: 20180928
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galante Joseph C
CENTRAL INDEX KEY: 0001632384
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 181094820
MAIL ADDRESS:
STREET 1: 111 TENTH AVENUE
STREET 2: SUITE 200
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2018-09-19
0
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001632384
Galante Joseph C
2525 WEST END AVENUE
SUITE 950
NASHVILLE
TN
37203
1
0
0
0
Common Stock
7350
D
Joseph C. Galante by /s/ Michael Bonner as attorney-in-fact
2018-09-28
EX-24.3_811133
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, I hereby appoint Michael Bonner and Jean W.
Marstiller, or any one of them, to act as my agent and attorney-in-fact for the
purpose of completing, executing and filing on my behalf with the Securities and
Exchange Commission, the NASDAQ Stock Market LLC or any other exchange or
self-regulatory body, any Form 3 "Initial Statement of Beneficial Ownership of
Securities", Form 4 "Statement of Changes in Beneficial Ownership of
Securities", Form 5 "Annual Statement of Beneficial Ownership of Securities",
Form 144 "Notice of Proposed Sale of Securities", Schedule 13D pursuant to Rule
13d-101 of the Securities Exchange Act of 1934, or any other similar form to
report securities ownership that may, in the opinion of any of them be
necessary, with respect to any transaction in securities of Cumberland
Pharmaceuticals Inc.
Nothing herein shall relieve me of the responsibility for the accuracy of the
information and representations contained in any Form 3, Form 4, Form 5, Form
144, Schedule 13D, or other similar form completed, executed and filed pursuant
to this power of attorney.
This power of attorney shall supersede all similar prior powers of attorney and
will remain effective as to the agents and attorneys-in-fact referred to above
until I revoke or amend it by written notice to such persons or until the
undersigned is no longer required to file Form 3, Form 4, Form 5, Form 144,
Schedule 13D or other similar form completed, executed and filed pursuant to
this power of attorney.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed on this 27th day of September 2018.
/s/ Joseph C. Galante
Joseph C. Galante